A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
- To evaluate the safety and tolerability of CU-40101 liniment as a single and multiple topical application in adult male androgenic alopecia subjects;
- To evaluate the pharmacokinetic (PK) characteristics of CU-40101 liniment administered as a single and multiple topical skin application in adult male subjects with androgenic alopecia.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Gingko Qiu
- Phone Number: 02152983119
- Email: medical.co@cutiatx.com
Study Locations
-
-
Hangzhou
-
Zhejiang, Hangzhou, China, 310052
- Recruiting
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Contact:
- Bo Jiang
- Phone Number: 0571-89713252
- Email: jiangbo@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject has provided written informaed consent.
- Subject is male, 18-55 years old.
- Subject has a clinical diagnosis of moderate to severe AGA in temple and vertex region, Ⅲ to Ⅶ on the Modified Norwood-Hamilton Scale.
- Subject has a body mass index(BMI) of 19 to 28 kg/㎡ inclusive and body weight not less than 50kg.
- According to the history, physical examination, vital signs, 12-lead electrocardiogram and laboratory examination results, the patient was in good health with no clinically significant abnormalities
- Subjects (including partners) are willing to take effective contraceptive measures voluntarily within 3 months from signing the informed consent to the last dose.
Exclusion Criteria:
- Allergic to the study drug or any ingredient in the study drug
- Skin damage or abnormality at the administration site may affect drug absorption or evaluation, such as dermatitis, scar, tattoo, sunburn, etc
- Subjects who currently have thyroid disease (including hyperthyroidism, hypothyroidism, etc.) or are currently receiving thyroxine replacement therapy. Thyroid function abnormalities on blood tests at the screening stage or thyroid ultrasound that the investigator judged to be clinically significant must be excluded
- Any surgical procedures performed within 3 months prior to screening, or planned during the study and within 1 month after the subject completed all study visits
- A history of clinically significant heart, liver, neurological, respiratory, hematological, digestive, immune, renal, or psychiatric disorders that the investigator believes may confound study results or affect drug absorption, distribution, metabolism, and excretion or place the subject at inappropriate risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Single Dose 1
0.0025%(0.025 mg/mL)
|
CU-40101,0.0025% CU-40101,0.005%
CU-40101,0.01%
CU-40101,0.02%
|
|
Experimental: Single Dose 2
0.005%(于0.05 mg/mL)
|
CU-40101,0.0025% CU-40101,0.005%
CU-40101,0.01%
CU-40101,0.02%
|
|
Experimental: Single Dose 3
0.01%(0.1 mg/mL)
|
CU-40101,0.0025% CU-40101,0.005%
CU-40101,0.01%
CU-40101,0.02%
|
|
Experimental: Single Dose 4
0.02%(0.2 mg/mL)
|
CU-40101,0.0025% CU-40101,0.005%
CU-40101,0.01%
CU-40101,0.02%
|
|
Experimental: Multiple Dose 1
0.05%(0.05 mg/mL)
|
CU-40101,0.0025% CU-40101,0.005%
CU-40101,0.01%
CU-40101,0.02%
|
|
Experimental: Multiple Dose 2
0.01%(0.01 mg/mL)
|
CU-40101,0.0025% CU-40101,0.005%
CU-40101,0.01%
CU-40101,0.02%
|
|
Experimental: Multiple Dose 3
0.02%(0.02 mg/mL)
|
CU-40101,0.0025% CU-40101,0.005%
CU-40101,0.01%
CU-40101,0.02%
|
|
Placebo Comparator: Placebo
Liniment containing anhydrous ethanol, propylene glycol and polyethylene glycol 400
|
CU-40101,0.0025% CU-40101,0.005%
CU-40101,0.01%
CU-40101,0.02%
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AE and SAE
Time Frame: Single dose 29 days; Multiple dose 39 days
|
TEAE and SAE will be summarized by dose grouping based on systematic organ Classification (SOC), preferred term (PT) and severity, as well as their relationship to the study drug.
Subjects who reported multiple adverse events within the same SOC and PT could only be counted once, according to the highest severity level.
|
Single dose 29 days; Multiple dose 39 days
|
|
Vital signs
Time Frame: Single dose 29 days; Multiple dose 39 days
|
Descriptive statistics summarizing changes in heart rate will be compared between baseline levels at each predetermined point in time.
|
Single dose 29 days; Multiple dose 39 days
|
|
Vital signs
Time Frame: Single dose 29 days; Multiple dose 39 days
|
Descriptive statistics summarizing changes in sitting blood pressure (systolic and diastolic) will be compared between baseline levels at each predetermined point in time.
|
Single dose 29 days; Multiple dose 39 days
|
|
Vital signs
Time Frame: Single dose 29 days; Multiple dose 39 days
|
Descriptive statistics summarizing changes in body temperature will be compared between baseline levels at each predetermined point in time.
|
Single dose 29 days; Multiple dose 39 days
|
|
12-lead ECG
Time Frame: Single dose 29 days; Multiple dose 39 days
|
The number of results of heart rate, QT, QTcF and PR interval will be collected. Descriptive statistics summarizing changes of parameters above will be compared between baseline levels at each predetermined point in time. |
Single dose 29 days; Multiple dose 39 days
|
|
Laboratory inspection
Time Frame: Single dose 29 days; Multiple dose 39 days
|
The number of results of blood routine examination, Blood Biochemical and routine urine examination will be collected Descriptive statistics summarizing changes of parameters above will be compared with baseline levels at each predetermined point in time.
|
Single dose 29 days; Multiple dose 39 days
|
|
Vital signs
Time Frame: Single dose 29 days; Multiple dose 39 days
|
Descriptive statistics summarizing changes in respiration will be compared between baseline levels at each predetermined point in time.
|
Single dose 29 days; Multiple dose 39 days
|
|
Assessment of topical skin tolerance
Time Frame: Single dose 29 days; Multiple dose 39 days
|
The number of erythema, burning/tingling, dryness, pruritus, desquamation of skin and hyperpigmentation after dosing.
|
Single dose 29 days; Multiple dose 39 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CU-40101-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.